公开(公告)号：US08071294B2

公开(公告)日：2011-12-06

申请号：US12625841

申请日：2009-11-25

申请人： Isabella T. Tai ,  Lan Bo Chen

发明人： Isabella T. Tai ,  Lan Bo Chen

IPC分类号： C12Q1/68 ,  G01N33/53 ,  A61K48/00

CPC分类号： A61K45/06 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/7048 ,  A61K33/24 ,  A61K38/17 ,  A61K38/39 ,  A61K48/00 ,  A61K2300/00

摘要： The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.

摘要翻译： 本发明涉及用于敏化癌症治疗的组合物和方法。 本发明提供了包含SPARC家族多肽或多核苷酸的组合物，以及含有SPARC家族多肽或多核苷酸的重组细胞。 本发明的组合物和方法可用于癌症治疗抗性的体外研究以及癌症的离体和体内治疗。

公开(公告)号：US07638272B2

公开(公告)日：2009-12-29

申请号：US11181115

申请日：2005-07-14

申请人： Isabella T. Tai ,  Lan Bo Chen

发明人： Isabella T. Tai ,  Lan Bo Chen

IPC分类号： C12Q1/00 ,  C12Q1/68 ,  G01N33/53 ,  A61K39/395 ,  A61K39/385

CPC分类号： A61K45/06 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/7048 ,  A61K33/24 ,  A61K38/17 ,  A61K38/39 ,  A61K48/00 ,  A61K2300/00

摘要： The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.

摘要翻译： 本发明涉及用于敏化癌症治疗的组合物和方法。 本发明提供了包含SPARC家族多肽或多核苷酸的组合物，以及含有SPARC家族多肽或多核苷酸的重组细胞。 本发明的组合物和方法可用于癌症治疗抗性的体外研究以及癌症的离体和体内治疗。

公开(公告)号：US06303157B1

公开(公告)日：2001-10-16

申请号：US09584220

申请日：2000-05-31

申请人： Mitsunori Ono ,  Lan Bo Chen

发明人： Mitsunori Ono ,  Lan Bo Chen

IPC分类号： A01N6500

CPC分类号： A61K31/366 ,  A61K31/365 ,  A61K47/40

摘要： This invention relates to a kava-kava lactone-containing product. Also disclosed is a method of preparing such a kava-kava lactone-containing product by extracting kava-kava lactones from crude kava-kava extracts with a solubilizing agent.

摘要翻译： 本发明涉及含有卡拉卡瓦内酯的产品。 还公开了一种通过用增溶剂从粗卡瓦卡瓦提取物中提取卡瓦卡诺内酯来制备这种含有卡拉卡含内酯的产品的方法。

公开(公告)号：US20180028631A1

公开(公告)日：2018-02-01

申请号：US15664098

申请日：2017-07-31

申请人： Lan Bo Chen

发明人： Lan Bo Chen

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  A61K39/395

CPC分类号： A61K39/0011 ,  A61K39/39558 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/03 ,  C07K2319/74

摘要： A chimeric antigen receptor containing (i) a single chain Fv that specifically binds to stage-specific embryonic antigen 4 and (ii) an endodomain from CD3ζ or FcεRIγ. Also provided is a nucleic acid encoding the chimeric antigen receptor and an expression vector that contains the nucleic acid operably linked to a promoter that is active in T cells. Furthermore, two similar methods for treating a tumor are disclosed. The first method includes (i) obtaining T cells from a subject, (ii) transducing the T cells in vitro with an expression vector encoding a chimeric antigen receptor that contains an scFv specifically recognizing stage-specific embryonic antigen 4, (iii) expanding the transduced T cells in vitro, and (iv) infusing the expanded transduced T cells into the subject. The second method includes, in place of step (ii) above, transducing the T cells in vitro with an expression vector encoding a chimeric antigen receptor that is specific for a tumor antigen other than stage-specific embryonic antigen 4, and further requires a step of administering an antibody against stage-specific embryonic antigen 4.

公开(公告)号：US20180028630A1

公开(公告)日：2018-02-01

申请号：US15664065

申请日：2017-07-31

申请人： Lan Bo Chen

发明人： Lan Bo Chen

IPC分类号： A61K39/00 ,  A61K39/39 ,  C07K14/705

CPC分类号： A61K39/0011 ,  A61K39/39 ,  A61K47/6415 ,  A61K47/646 ,  A61K47/68 ,  A61K2039/55572 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6056 ,  A61K2039/62 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/705 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/74

摘要： An immunogenic composition that includes a glycoconjugate containing a fusion protein composed of an immunoglobulin gamma Fc domain fused to a tumor-associated antigen, the fusion protein being cross-linked to an azido-modified stage-specific embryonic antigen 4 conjugated to diphtheria toxoid cross-reactive material 197; and α-galactosylceramide C34 or α-glucosylceramide C34. Also provided are methods for treating cancer by administering the immunogenic composition to a patient.

公开(公告)号：US06537592B2

公开(公告)日：2003-03-25

申请号：US09962514

申请日：2001-09-24

申请人： Mitsunori Ono ,  Lan Bo Chen

发明人： Mitsunori Ono ,  Lan Bo Chen

IPC分类号： A01N6500

CPC分类号： A61K31/366 ,  A61K31/365 ,  A61K47/40

摘要： This invention relates to a kava-kava lactone-containing product. Also disclosed is a method of preparing such a kava-kava lactone-containing product by extracting kava-kava lactones from crude kava-kava extracts with a solubilizing agent.

公开(公告)号：US4774250A

公开(公告)日：1988-09-27

申请号：US033149

申请日：1987-04-02

申请人： Lan Bo Chen ,  Wilbert J. Humphlett

发明人： Lan Bo Chen ,  Wilbert J. Humphlett

IPC分类号： A61K31/44 ,  A61K31/4433 ,  C07D409/04 ,  C07D409/14

CPC分类号： A61K31/44

摘要： There are described an anti-cancer composition and a method of treating differentiated carcinomas or melanoma, Featuring a suitable carrier and particular 2,4,6-tri(aryl or heteroaryl) thiapyrylium dyes.

公开(公告)号：US20180030124A1

公开(公告)日：2018-02-01

申请号：US15664088

申请日：2017-07-31

申请人： Lan Bo Chen

发明人： Lan Bo Chen

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2878 ,  C07K16/30 ,  C07K2317/24 ,  A61K2300/00

摘要： A method for treating a tumor by administering an antibody or antibody fragment that binds specifically to stage-specific embryonic antigen 4, and an agent that enhances T cell anti-tumor responses. Also provided is a pharmaceutical composition for treating a tumor. The pharmaceutical composition contains an anti-SSEA4 antibody or antibody fragment, an agent that enhances T cell responses, and a pharmaceutically acceptable excipient.

公开(公告)号：US20180028634A1

公开(公告)日：2018-02-01

申请号：US15664197

申请日：2017-07-31

申请人： Lan Bo Chen

发明人： Lan Bo Chen

IPC分类号： A61K39/00 ,  A61K39/385 ,  C07K16/30 ,  A61K39/395

CPC分类号： A61K39/0011 ,  A61K39/385 ,  A61K39/39 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/55511 ,  A61K2039/6037 ,  C07K16/3076

摘要： A method for treating a tumor includes administering (i) a vaccine that contains stage-specific embryonic antigen 4 conjugated to a carrier, (ii) an antibody that binds specifically to SSEA-4, and (iii) immune cells expressing a chimeric antigen receptor that specifically binds to SSEA-4. The tumor, which expresses SSEA-4, can be a breast, colon, gastrointestinal, kidney, lung, liver, ovarian, pancreatic, rectal, stomach, testicular, thymic, cervical, prostate, bladder, skin, nasopharyngeal, esophageal, oral, head and neck, bone, cartilage, muscle, lymph node, bone marrow, or brain tumor.

公开(公告)号：US20180028633A1

公开(公告)日：2018-02-01

申请号：US15664151

申请日：2017-07-31

申请人： Lan Bo Chen

发明人： Lan Bo Chen

IPC分类号： A61K39/00 ,  A61K47/68 ,  C07K14/725 ,  C07K16/18

CPC分类号： A61K39/0011 ,  A61K47/6813 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K14/70503 ,  C07K14/7051 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0638 ,  C12N5/0646

摘要： A method for treating a tumor in a subject by administering at least three of the following treatment modalities: (i) an antibody, (ii) T cells bearing a first chimeric antigen receptor (CAR), (iii) NK cells bearing a second CAR, and (iv) NKT cells bearing a third CAR. The antibody binds specifically to stage-specific embryonic antigen 4 and each CAR contains a scFv that also binds specifically to SSEA4.